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Antibiotics that interfere with translation, when combined, interact in diverse and difficult-to-
predict ways. Here, we explain these interactions by “translation bottlenecks”: points in the
translation cycle where antibiotics block ribosomal progression. To elucidate the underlying
mechanisms of drug interactions between translation inhibitors, we generate translation
bottlenecks genetically using inducible control of translation factors that regulate well-
defined translation cycle steps. These perturbations accurately mimic antibiotic action and
drug interactions, supporting that the interplay of different translation bottlenecks causes
these interactions. We further show that growth laws, combined with drug uptake and
binding kinetics, enable the direct prediction of a large fraction of observed interactions, yet
fail to predict suppression. However, varying two translation bottlenecks simultaneously
supports that dense traffic of ribosomes and competition for translation factors account for
the previously unexplained suppression. These results highlight the importance of “con-
tinuous epistasis” in bacterial physiology.
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Inhibiting translation is one of the most common antibioticmodes of action, crucial for restraining pathogenic bacteria1.Antibiotics targeting translation interfere with either the
assembly or the processing of the ribosome, or with the proper
utilization of charged tRNAs and translation factors (Fig. 1a, b;
Table 1)2. Still, the exact modes of action and physiological
responses to many such translation inhibitors are unclear.
Responses to drug combinations, which may offer effective ways
to combat antibiotic resistance3, are even harder to understand.
Apart from their clinical relevance, antibiotic combinations pro-
vide powerful quantitative and controlled means of studying
perturbations of cell physiology4—conceptually similar to studies
of epistasis between double gene knockouts5,6. Recently,
mechanism-independent mathematical approaches to predict the
responses to multi-drug combinations were proposed7,8, yet these
approaches rely on prior knowledge of pairwise drug interactions,
which are diverse and have notoriously resisted prediction. They
include synergism (drug effect is stronger than predicted),
antagonism (drug effect is weaker), and suppression (one of the
drugs loses potency)9,10 (Fig. 1c). To design optimized treat-
ments, the ability to predict or alter drug interactions is crucial.
Such predictions would be facilitated by understanding their
underlying mechanisms11.
Predictions of drug interactions should ideally only require
information about responses to individual antibiotics. Established
null models of drug interactions are based on mechanism-
independent expectations such as Loewe additivity (Fig. 1)12,
which mainly serve as a reference for classifying drug interac-
tions. There is currently no null model that captures well-
understood processes such as drug uptake, target binding, and the
physiological response to target inhibition, which are relevant for
all drugs that share the same target. Any deviations from pre-
dictions of such a null model could expose drug interactions that
cannot be explained by established biological and physical pro-
cesses alone. Consequently, an improved null model could offer a
plausible mechanism for some drug interactions and at the same
time expose more complex situations where additional molecular
or physiological details are crucial.
Translation is a fundamental, yet complex multi-step process
that still lacks a comprehensive quantitative description. A key
step toward such a description are bacterial “growth laws,” which
quantitatively capture the compensatory upregulation of the
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Fig. 1 Antibiotics targeting different translation steps show diverse drug interactions. a, b Schematic of the translation cycle and translation inhibitors.
Translation factors are shown in dark gray boxes. The stability of the large subunit is mediated by Der and initiation by initiation factors (IFs). Elongation
factors Tu and G (EF-Tu, EF-G) catalyze ribosome progression. The release of GDP from EF-Tu is facilitated by EF-Ts. Release factors (RFs) facilitate the
ejection of the finished peptide from the ribosome, whose recycling is mediated by the factor for ribosome recycling (Frr). Translation inhibitors are shown
in white boxes (abbreviations in Table 1). c Examples of response surfaces for different antibiotic combinations corresponding to different interaction types
(left column) and examples of growth curves (right column). Left: dose–response surfaces for different drug combinations. Grayscale shows a normalized
growth rate as a function of concentrations of two antibiotics. Drug interactions are determined based on the shape of the contour lines of equal growth
(isoboles). If the addition of the second drug has the same effect as increasing the concentration of the first, the isoboles are straight lines12. Deviations
from this additive expectation reveal synergism (the combined effect is stronger and isoboles curve towards the origin), antagonism (the effect is weaker
and isoboles curve away from the origin), or suppression (at least one of the drugs loses potency due to the other). Symbols show drug conditions in which
growth curves shown in the right column were measured. Right: Growth curves (i.e., time courses of luminescence) for four conditions (no drug, individual
drugs, and combination); thin gray line shows the additive expectation of the growth curve for the combined stress; luminescence (photon count-per-
second) on y-axes is a proxy for the number of bacteria (Methods). Symbols on the growth curves indicate the condition used: no symbol, triangle, square
and a circle correspond to no drug, CHL-only, the second drug only (see left plots), and the combination of both, respectively. The growth curves were
shifted in time to originate from the same point at time zero. d Drug-interaction network of translation inhibitors. Color-code is as in (c); dashed gray lines
denote additivity. Each drug interaction was measured twice.
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translational machinery in response to perturbations of transla-
tion13. Growth laws have enabled a model that explains the
growth-rate dependent bacterial susceptibility to individual
translation inhibitors14. Well-defined translation steps cannot
only be perturbed chemically2,15, but also genetically, as these
steps are regulated by translation factors—specialized proteins
that mediate the stability of ribosomal subunits, catalyze the
assembly of 70S ribosomes and initiation, deliver charged tRNAs
to the ribosome, release finished peptides, and mediate ribosome
recycling (Fig. 1a). Both genetic and chemical perturbations
obstruct the progression of ribosomes along the translation cycle,
which generally results in a lower growth rate. Comparing the
effects of antibiotics to those of precisely defined genetic pertur-
bations offers an opportunity to elucidate the mechanisms
responsible for drug interactions between translation inhibitors
and could quantitatively test the equivalence of genetic and
chemical perturbations of bacterial physiology.
Here, we hypothesize that a key determinant of interactions
between pairs of translation inhibitors are the specific steps in the
translation cycle where the two inhibitors halt ribosomal pro-
gression (Fig. 1a). As a second key determinant of these drug
interactions, we consider the compensatory physiological
response to translation inhibition captured quantitatively by
ribosomal growth laws13 together with the kinetics of antibiotic
transport and ribosome binding. We show that these determi-
nants suffice to explain most drug interactions between transla-
tion inhibitors and that these interactions can be predicted solely
from known responses to the individual drugs. To establish this
result, we use a combination of precise growth measurements,
quantitative genetic perturbations of the translation machinery,
and theoretical modeling.
Results
Diverse drug interactions between translation inhibitors. To
systematically map the network of drug interactions between
translation inhibitors, we selected eight representative antibiotics
that interfere with different stages of translation and bind to
different sites on the ribosome (Fig. 1a, b; Table 1). We deter-
mined high-resolution dose–response surfaces for all pairwise
combinations of these antibiotics by measuring growth rates in
two-dimensional drug concentration matrices using a highly
precise technique based on bioluminescence5,16,17 (Fig. 1c and
Supplementary Fig. 1; Methods). The shape of the contour lines,
along which growth rate is constant in two-drug space, reveals the
drug interaction type (Fig. 1c). To quantify the drug interactions,
we defined the Loewe interaction score LI, which integrates
deviations from Loewe additivity (Supplementary Methods). In
this way, we characterized all twenty-eight pairwise interactions
and constructed the interaction network between the translation
inhibitors (Fig. 1d).
The translation inhibitor interaction network (Fig. 1d) we
measured has several notable properties. First, antibiotics with
similar mode of action tend to exhibit additive drug interactions:
In particular, there are purely additive interactions between
capreomycin (CRY) and fusidic acid (FUS), which both inhibit
translocation, and streptomycin (STR), which interferes with
tRNA binding and also slightly lowers the translocation rate.
Chloramphenicol (CHL) and lincomycin (LCY), which both
inhibit peptide bond formation, interact additively as well. This
observation is consistent with the view that drugs with similar
mode of action can substitute for one another. Second,
kasugamycin (KSG) is a prominent hub in the network: it shows
almost exclusively antagonistic and suppressive interactions with
other translation inhibitors. Third, we identified a previously
unreported synergy between CRY and CHL. Several other
interactions confirm previous reports. For example, synergy
between erythromycin (ERM) and tetracycline (TET) was
observed before5,18. Additivity between CHL and TET was also
reported; moreover, this interaction proved to be highly robust to
genetic perturbations11. Finally, antagonism and suppression are
more common in the translation inhibitor interaction network
than synergy, consistent with a general prevalence of antagonistic
interactions between antibiotics19. We reasoned that general
trends like the prevalence of antagonism in the drug interaction
network may be due to a general physiological response to
translation inhibition.
Growth-law based biophysical model does not explain sup-
pression. As a first step toward understanding the origin of the
observed drug interactions, we developed a mathematical model
that predicts such interactions from the effects of the individual
drugs alone. We generalized a biophysical model for the effect of
a single antibiotic on bacterial growth14 to the situation where
two antibiotics are present simultaneously. In the spirit of ref. 14,
our model aims to predict the response to a pair of “generic”
translation inhibitors whose action leads to a physiological
response that obeys established bacterial growth laws13. Con-
siderable experimental support from observations of the effects of
Table 1 Translation-targeting antibiotics used in this study.
Antibiotic Abbreviation IC50 [μgmL−1] Mode of action, notes
Chloramphenicol CHL 1.55 ± 0.06 Binds in the vicinity of the peptidyl transferase center (PTC) on the 50S subunit2; partially overlaps
with the aminoacyl moiety of tRNA on the A-site61.
Lincomycin LCY 280 ± 10 Lincosamide antibiotic; binds next to PTC and interferes with peptide bond formation2.
Erythromycin ERM 25 ± 1 Macrolide antibiotic that binds further down the nascent peptide exit channel (Fig. 1b), and
physically blocks the egress of some newly synthesized peptide chains2. Some nascent peptide
chains can bypass this block, leading to proteome modification62,63.
Kasugamycin KSG 127 ± 5 Aminoglycoside; interferes with translation initiation by destabilization of the P-site initiator tRNA
and mRNA64.
Streptomycin STR 2.55 ± 0.02 Aminoglycoside; interferes with the tRNA binding on the A-site and marginally lowers the rate of
translocation2,15,33. It additionally induces mistranslation15.
Tetracycline TET 0.32 ± 0.01 Interferes with the binding of aminoacyl-tRNA to the A-site65.
Capreomycin CRY 24 ± 1 Inhibits translocation by binding to the interface between subunits and stabilization of the
ribosome in the pre-translocation state of the ribosome. It only binds the 70S ribosome and not
the individual subunits66.
Fusidic acid FUS 64 ± 3 Inhibits elongation by preventing dissociation of EF-G from the ribosome and lowers the rate of
ribosome recycling67.
Antibiotic names, abbreviations, IC50 measured for E. coli MG1655 in LB medium at 37°C, and notes on their mode of action.
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diverse chemical and genetic perturbations on translation
strengthens the generality of growth laws20–22. This parsimonious
approach keeps the number of unknown model parameters to a
minimum. Cases, where the response to a drug pair deviates from
the predictions of this physiologically relevant null model, indi-
cate that more complex mechanisms—specific to one or both of
the drugs used—are essential for understanding the drug
interaction.
The model consists of ordinary differential equations that
capture passive antibiotic transport into the cell, binding to the
ribosome (Fig. 2a, b), dilution of all molecular species due to cell
growth, and the physiological response of the cell to the
perturbation (Fig. 2c). Antibiotic uptake and efflux are char-
acterized by permeability constants. Ribosome binding obeys
mass-action kinetics and, in particular, captures the extent to
which binding is reversible. The cell’s physiological response to
translation inhibition is described by bacterial growth laws13,14,
which quantitatively connect the growth rate to the total
abundance of ribosomes when the growth rate is varied by the
nutrient quality of media or by translation inhibitors. In the
model, growth laws determine the regulation of ribosome
synthesis in response to translation inhibitors and relate the
concentration of free ribosomes to the growth rate. For a single
such translation inhibitor, the shape of the dose–response curve
depends solely on a response parameter α that merges multiple
kinetic parameters into a single number (Supplementary
Information and ref. 14,23). Notably, all parameters of this model
can be inferred from the dose–response curves of individual drugs
(Fig. 2d).
When two different antibiotics are present, separate variables
are needed to describe ribosomes that are bound by either of the
antibiotics individually or simultaneously by both (Fig. 2a, b).
Apart from notable exceptions such as the lankamycin-lankacidin
and dalfopristin-quinupristin combinations24,25), the biochemical
details of direct physical interactions between antibiotics on the
ribosome are largely unknown. Therefore, we assumed that the
antibiotic binding and unbinding rates are independent of any
previously bound antibiotic; alternatively, to describe competition
for the same binding site, we assumed that double-bound
ribosomes cannot form (Fig. 2b). These two cases do not require
any modifications of the binding parameters inferred from single-
drug dose–response curves. The resulting model directly predicts
dose–response surfaces rather than fitting them by adjusting free
parameters. As a result, this biophysical model provides a well-
defined mechanistic null model informed by cell physiology.
Using this model, we calculated the predicted response surfaces
for all translation inhibitor pairs and compared them to the
experimentally measured surfaces (Supplementary Methods,
Fig. 2e, and Supplementary Fig. 2). Certain drug interactions
were correctly predicted by this approach (e.g., KSG-ERM, ERM-
TET in Fig. 2e), indicating that binding kinetics and growth
physiology alone suffice to explain these interactions. Correctly
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Fig. 2 Mathematical model partially predicts drug interactions. a Schematic of antibiotic binding and transport into the cell. Antibiotics (circles) bind to
the unbound ribosomes (gray) in the first binding step (above dashed line); bound ribosomes can be bound by a second antibiotic (second binding step;
below dashed line). b Schematic of antibiotics binding independently (top) or competing for the same binding site (bottom). c Growth laws link intracellular
ribosome concentration to the growth rate. Solid line: ribosome concentration when the growth rate is varied by varying nutrient quality; dashed lines:
ribosome concentration when the growth rate is lowered by perturbation of translation. Circles show data from ref. 14. d Data points are dose–response
curves for ERM and KSG; lines show the best-fits of the mathematical model. The best-fit values of the response parameter α that encapsulates kinetic and
physiological parameters (Supplementary Information) are shown. Both shallow (top panel, ERM) and steep (bottom panel, KSG) dose–response curves
are observed. e Examples of predicted dose–response surfaces. The scatter plot depicts the correlation between predicted and measured growth rates.
Means and error bars (standard deviation) of predicted growth rates are estimated from n= 100 bootstrap repetitions. The binding scheme assumed is
indicated on the bottom right and Pearson’s ρ on the top left. Predicted and measured dose–response surfaces are shown below the scatter plot. Color of
20% isobole (bottom) denotes the type of predicted interaction. The model correctly predicts response surfaces for KSG-ERM, ERM-TET, and ERM-CHL,
yet it fails to predict the interaction between STR and KSG.
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predicted drug interactions include additive cases which often
involve antibiotics that have either similar modes of action (CRY-
FUS, CHL-LCY) or partially overlapping binding sites (CHL-
LCY, ERM-CHL)2. For the latter, the assumption that the
formation of the doubly-bound ribosome population is prohib-
ited, which yields an additive response surface, offers even better
agreement with the experimental data (Fig. 2e). Occasionally,
drug interactions are better explained if competitive binding is
assumed (e.g., CHL-TET) even though the binding sites of the
antibiotics involved do not overlap.
Other drug interactions clearly deviated from the model
predictions. An example is the suppressive/antagonistic interac-
tion between STR and KSG, which was predicted to be additive
(Fig. 2e). Such clear deviations could originate from direct
molecular interactions of the drugs on the ribosome, and thus be
specific for every drug pair; we explore this situation theoretically
in ref. 23. Alternatively, these drug interactions could result from
the multi-step structure of the translation cycle itself, which our
model does not take into account. Simple partitioning of
ribosomes into different populations that are susceptible to
different antibiotics does not alter the drug interaction (Supple-
mentary Methods). In the most complex cases, drug interactions
could result from drug effects that are unrelated to the primary
drug target11, in particular from effects on drug uptake or
efflux26. We focused on the plausible hypothesis that drug
interactions are caused by the interplay of ribosomes halted in
different stages of the translation cycle such as initiation,
translocation, recycling, etc. (Fig. 1).
Inducible translation bottlenecks affect antibiotic efficacy. To
test this hypothesis, we developed a technique for measuring how
halting ribosomes in different stages of the translation cycle
affects the efficacy of various antibiotics. Specifically, we imposed
artificial bottlenecks in translation by genetically limiting the
expression of translation factors that catalyze well-defined
translation steps20. We constructed E. coli strains with transla-
tion factor genes under inducible control of a synthetic pro-
moter27. These genes were integrated into the chromosome
outside of their endogenous loci and the endogenous copy of the
gene was disrupted (Fig. 3a; Methods). This procedure yielded six
strains that enable continuous control of key translation processes
(Fig. 3b): stabilization of the 50S subunit (der), initiation (infB),
delivery of charged tRNAs (tufA/B), release of GDP from elon-
gation factors (tsf), translocation (fusA) and recycling of ribo-
somes (frr)28.
Reducing translation factor expression by varying the inducer
concentration resulted in a gradual decrease in growth which
stopped at almost complete cessation of growth, reflecting the
essentiality of translation factors (Fig. 3c, Methods, and
Supplementary Fig. 3a). Since the endogenous regulation of
translation factors generally follows that of the translation
machinery29–32, limiting the expression of a single translation
factor imposes a highly specific bottleneck as all other
components get upregulated. Any global feedback regulation is
left intact as we removed the factor from its native operon.
Similar genetic perturbations further conform to bacterial growth
laws13,20,21, supporting that translation factor deprivation is a
suitable means of assessing responses to targeted perturbations of
translation. While antibiotics often have secondary targets and
other non-specific effects on the cell, thus obfuscating experi-
ments, translation factor deprivation is highly specific. Our
synthetic strains offer precise control over artificial translation
bottlenecks that determine the rates of different translation steps
and enable disentangling phenomena that are caused by the
primary mode of action of antibiotics from those that result from
other effects of these drugs.
We used these synthetic strains to assess the impact of
bottlenecks on antibiotic efficacy. We measured growth rates over
a two-dimensional matrix of concentrations of inducer and
antibiotic for each of the six strains (Fig. 3c; Methods and
Supplementary Information). To assess if the action of the antibiotic
is independent of the translation bottleneck, we analyzed these
experiments using a multiplicative null expectation. Note that
additivity, as used for antibiotics (Fig. 1c), is not a suitable null
expectation here since the responses to increasing concentrations of
antibiotic and inducer are opposite. However, if antibiotic action is
independent of the translation bottleneck, the growth rate should be
a product of the relative growth rates of each of the two
perturbations acting individually. Independence implies that the
dose–response surface is obtained as a multiplication of the
antibiotic dose–response and the translation factor induction curve.
Deviations from independence indicate a nontrivial interaction
between the bottleneck and the antibiotic action.
We systematically identified interactions between translation
inhibitors and bottlenecks by their deviation from independence. In
general, antibiotic action can be alleviated or aggravated by a given
bottleneck, i.e., the bacteria can be less or more sensitive to the
antibiotic due to the bottleneck, respectively. We quantified the
magnitude of these effects by bottleneck dependency (BD) scores
(Supplementary Methods) and collected them into a single
bottleneck dependency vector per antibiotic. The components of
this vector describe the interactions between the antibiotic and all
six translation bottlenecks. Bottleneck dependency vectors were
diverse (Fig. 3d), indicating that bottlenecks at different stages of the
translation cycle differentially affect antibiotic efficacy. These results
are consistent with the hypothesis that the high diversity of drug
interactions between translation inhibitors (Fig. 1d) originates in the
diversity of translation steps targeted by the drugs (Fig. 1a).
The bottleneck dependency vector of a given antibiotic
provides a quantitative, functional summary of its interactions
with the translation cycle. In this sense, it is a characteristic
“fingerprint” of the antibiotic. Clustering of antibiotics based on
their bottleneck dependency vectors (Supplementary Informa-
tion) robustly grouped antibiotics with a similar mode of action
(CRY and FUS, LCY, and CHL in Fig. 3e, respectively). Notably,
this approach separated the translocation inhibitors CRY and
FUS from STR, which only weakly affects translocation33. Drug
interactions between antibiotics from the same cluster were
strictly additive (Figs. 1d and 3e). These results show that
interactions of antibiotics with translation bottlenecks have
explanatory power for drug mode of action and can expose
antibiotics acting as substitutes for one another.
While the clustering of certain antibiotics can be rationalized
from their presumed modes of action, this is more challenging for
others. To further assess the value of this analysis, we measured
bottleneck dependencies for three additional antibiotics: lamo-
trigine (LAM), trimethoprim (TMP), and nitrofurantoin (NIT).
As we elaborate in the Supplementary Discussion, using drugs
with a defined mode of action (LAM and TMP) corroborates the
utility of clustering by bottleneck dependencies, while the
similarity of STR to NIT, which has multiple modes of action,
suggests a plausible reason for the separation of STR from other
clusters of translation inhibitors.
Effects of translation bottlenecks predict drug interactions. We
reasoned that the effects of translation bottlenecks on antibiotic
action should also have predictive power for drug interactions
between translation inhibitors. We, therefore, sought a quantitative
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way of probing the contribution of translation bottlenecks to drug
interactions between translation inhibitors.
Ribosomes progress through the translation cycle in a sequence
of steps (Fig. 4a). Antibiotics and genetic translation bottlenecks
hinder this progression by reducing the transition rates between
these steps. If an antibiotic specifically targets a single translation
step and reduces the same transition rate as a genetic translation
bottleneck, the effects of the drug and the bottleneck should be
equivalent, i.e., the consequences of any perturbation elsewhere in
the translation cycle should be independent of the exact means by
which such a reduction is achieved (Fig. 4b).
To establish the equivalence of specific translation bottlenecks
and antibiotic action, we first transformed the measurements of
growth rate as a function of translation factor induction into
dose–response curves of a corresponding idealized antibiotic that
targets a single translation step with perfect specificity. In essence,
this procedure converts inducer concentrations into equivalent
antibiotic concentrations: the two concentrations are identified as
equivalent if they lead to the same relative growth rate (Fig. 4c, d;
Supplementary Methods). If the perturbations of factor and
antibiotic are equivalent, then the true and the idealized antibiotic
should act as substitutes for each other, and exhibit an additive drug
interaction. Conversely, we can use this comparison (Fig. 4e and
Supplementary Fig. 4) to test systematically if the action of
antibiotics is quantitatively equivalent to specific translation
bottlenecks.
We found that the effect of certain translation inhibitors is
almost perfectly mimicked by translation bottlenecks. Within our
selection of antibiotics, several strong candidates for equivalent
perturbations exist (Fig. 1a): CRY, FUS, and potentially STR with
EF-G (translocation); KSG with IF2 (initiation); and TET with
EF-Tu (tRNA-delivery). For example, remapping the response to
CRY and EF-G yields an additive surface (Fig. 4e, f), corroborat-
ing that CRY and the EF-G translocation bottleneck are
equivalent perturbations. In contrast, if the bottleneck is not
equivalent to the drug, remapping does not yield an additive
response surface; an example is CRY and the recycling bottleneck
(Fig. 4g). Occasionally, marginal effects dominate the apparent
equivalence: STR lowers translocation rate only two-fold33, but
inhibiting translocation by deprivation of EF-G is still the best
mimic of STR. In general, demonstrating that the action of an
antibiotic is equivalent to a specific translation bottleneck
provides strong quantitative evidence for its primary mode of
action, since translation factors control individual steps with high
specificity.
In contrast, the common approach of overexpressing the drug
target does not provide useful insights into the mode of action of
ribosome-targeting antibiotics. Simple overexpression requires a
well-defined drug target like a single protein; overexpressing the
ribosome is impractical34 and would not help distinguish the
precise action of different ribosome-targeting antibiotics. Even for
less complex drug targets, the interpretation of overexpression
assays is challenging35. Still, we tested if simple overexpression of
translation factors can provide similar insights into the mode of
action of TET as translation bottlenecks. Overexpression of
translation factors only weakly affected antibiotic efficacy
(Supplementary Fig. 8). The effects of overexpressing different
translation factors were not specific for antibiotic mode of action
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(Supplementary Fig. 8). Hence, unlike the depletion of translation
factors, their overexpression provides no information about drug
interactions with other antibiotics.
For antibiotics that are equivalent to specific translation factors
(Fig. 4f–i), drug interactions with other antibiotics can be directly
predicted from translation bottleneck measurements. In practice,
this is done by remapping the antibiotic-translation factor
response surfaces as described above (Fig. 5a–c). Unlike the
predictions of the biophysical model (Fig. 2), the predictions made
in this way are not based on a mathematical model, but rather on
empirical effects of genetic perturbations, which are quantitatively
converted into equivalent drug effects; in particular, they are
independent of the assumptions underlying the biophysical model.
While the biophysical model is only valid for antibiotics that
conform to bacterial growth laws, the predictions based on the
observed effects of translation bottlenecks are independent of
whether or not the growth laws hold for the specific perturbations
of translation used. The resulting prediction will be faithful if the
drug interaction originates exclusively from the interplay of two
translation bottlenecks.
Drug interactions predicted using this procedure were often
highly accurate (Fig. 5). In particular, some of the most striking
cases of antagonistic and suppressive interactions were
correctly predicted. For example, the prediction of antagonism
between CHL and KSG was quantitatively correct (Fig. 5c, d).
The same interactions were correctly predicted for LCY (Fig. 5f),
which is similar to CHL (Figs. 1a, b and 3e). Remapping
qualitatively accounted for nearly all observed interactions of
KSG with quantitative agreement in several cases (Supplemen-
tary Fig. 5), including the previously unexplained KSG-STR
interaction (Fig. 5f). Further, suppression of FUS by CHL was
correctly predicted: FUS loses potency when CHL is added
(Fig. 5f). In this way, several drug interactions with previously
elusive mechanisms are explained by the interplay of the
specific steps in the translation cycle that are targeted by the
antibiotics involved.
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Remapping correctly predicted additive drug interactions
between antibiotics that could not be easily explained by the
biophysical model. As noted above, additivity between CHL-TET
was predicted for the competitive binding scheme; yet, compe-
titive binding is difficult to rationalize as TET and CHL bind to
different subunits. Similarly, the additive pair KSG-ERM is even
more puzzling since, unlike ERM, KSG does not act within the
elongation cycle (Supplementary Discussion).
For some antibiotic pairs, the predictions based on equivalent
translation bottlenecks failed to explain the observed drug
interactions (e.g., for LCY-CRY and CHL-CRY; Supplementary
Information), indicating that these interactions have origins
outside of the translation cycle. We expect that these cases are
often due to idiosyncrasies and secondary effects of the drugs,
which will require separate in-depth characterization in each case.
In contrast, our results show that various non-trivial drug
interactions between antibiotics are systematically explained by
the interplay of specific translation bottlenecks caused by the
antibiotics. While the growth-law based biophysical model
already explained ≈57% (16 of 28) of the observed interactions
(Supplementary Fig. 2), these included many weak or additive
interactions; the most striking suppressive interactions were only
captured after taking into account the multi-step nature of
translation (Supplementary Fig. 5), thereby increasing the
explained fraction to ≈71% (20 of 28).
If suppressive drug interactions are caused by the interplay of
different translation bottlenecks alone, it should be possible to
recapitulate these interactions in a purely genetic way. We thus
expanded our translation bottleneck approach by introducing
multiple genetic bottlenecks in the same cell.
Double titration of translation factors emulates suppression.
We focused on the interactions between initiation inhibitors
(such as KSG) and translocation inhibitors (such as CRY and
FUS), which were exclusively antagonistic or suppressive
(Fig. 1d). Moreover, the initiation inhibitor KSG alleviated a
genetic translocation bottleneck and an initiation bottleneck
suppressed the effect of the translocation inhibitor FUS (Fig. 3c).
These observations suggest that a universal mechanism underlies
the suppression between initiation and translocation inhibitors.
We constructed a synthetic strain that enables simultaneous
independent control of initiation and translocation factor levels.
We integrated the initiation and translocation factors outside
their native loci under the tight control of promoters inducible by
isopropyl β-D-1-thiogalactopyranoside (IPTG) and anhydrote-
tracycline (aTc), respectively, in a strain in which their
endogenous copies were deleted (Fig. 6a and Supplementary
Fig. 6; Methods). To maximize the precision of induction that is
achievable with different inducer concentrations, we put both
factors under negative autoregulatory control by chromosomally
integrated repressors13,36. The resulting strain showed virtually
no growth when at least one of the inducers was absent but
unrestricted wild type growth in the presence of both inducers
(Fig. 6b). These observations confirm that both translation factors
are essential and show that their expression can be varied over the
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entire physiologically relevant dynamic range, thus enabling
quantitative genetic control of two key translation processes.
Curtailing translation initiation suppresses the effect of a
genetic translocation bottleneck. We determined the bacterial
response to varying translocation and initiation factor levels by
measuring growth rates over finely resolved two-dimensional
concentration gradients of both inducers. The resulting response
surface clearly showed that inhibition of initiation alleviates the
effect of translocation inhibition (Fig. 6c and Supplementary
Fig. 6). This phenomenon exactly mirrors the antibiotic-antibiotic
(KSG-FUS, Fig. 1d) and bottleneck-antibiotic interactions
(initiation-FUS, Fig. 3c). An all-or-nothing approach (Fig. 6b),
analogous to common genetic epistasis measurements37, would
miss this suppressive effect, highlighting the importance of using
quantitatively controlled perturbations. Taken together, these
data show that the interplay of translation initiation and
translocation alone is sufficient to produce strong suppression:
dialing down initiation cranks up growth stalled by translocation
bottlenecks. The widespread suppression between antibiotics
targeting initiation and translocation is thus explained as a
general consequence of the combined inhibition of specific
translation steps alone.
What is the underlying mechanism of the suppressive
interaction between initiation and translocation inhibitors?
We hypothesized that this suppression results from alleviating
ribosome “traffic jams” that occur during translation of
transcripts at low translocation rates (Fig. 6d). The traffic of
translating ribosomes that move along mRNAs can be dense38.
When a ribosome gets stuck, e.g., due to a low translocation rate,
it blocks the translocation of subsequent ribosomes. The resulting
situation is similar to a traffic jam of cars on a road. Traffic jams
can form due to the asynchronous movement and stochastic
progression of particles in discrete jumps, which is a good
approximation for the molecular dynamics of a translating
ribosome. If particle progression were deterministic and syn-
chronous, no traffic jams would form. A classic model of queued
traffic progression, which can be applied to translation39,40, is the
totally asymmetric simple exclusion process (TASEP)41,42.
We developed a generalization of the TASEP that describes the
traffic of translating ribosomes on mRNAs and takes into account
the laws of bacterial cell physiology. There are several differences
between the classic TASEP and translating ribosomes moving
along a transcript. First, a ribosome does not merely occupy a
single site (codon), but rather extends over 25 nucleotides (≈8.33
codons)43,44. Second, the total number of ribosomes in the cell is
finite and varies as dictated by bacterial growth laws13,45. Third,
translation steps are mediated by translation factors that bind to
the ribosome in a specific state and push the ribosome into
another state28. These transitions are stochastic with rates that
depend on the abundance of ribosomes in a specific state and on
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the abundance of translation factors available to catalyze the step.
Thus, the initiation- and translocation-attempt rates, which are
constant in the classic TASEP, depend on the state of the system.
We formulated a generalized TASEP that captures these
extensions, estimated all of its parameters based on literature,
and derived the model equations analytically (Methods and
Supplementary Information). The resulting growth rate was
calculated numerically. In brief, our generalized TASEP model
provides a physiologically realistic description of the factor-
mediated traffic of ribosomes on multiple transcripts.
Without any free parameters, this generalized TASEP qualita-
tively reproduced the suppressive effect of lowering the initiation
rate under a translocation bottleneck (Fig. 6e). This suppression
results from a phase transition between the translocation- and the
initiation-limited regime (Supplementary Information). In the
translocation-limited regime (black arrow in Fig. 6e), ribosome
traffic is dense and cannot be further increased by boosting the
initiation attempt rate. Upon decreasing the initiation attempt
rate ζ (green arrow in Fig. 6e), a phase transition to the initiation-
limited regime occurs. Beyond the critical point of this phase
transition (green triangle in Fig. 6e), the elongation velocity, and
with it the growth rate, begins to increase with decreasing
initiation attempt rate. Hence, ultimately, a non-equilibrium
phase transition in which ribosome traffic jams dissolve underlies
the suppressive effect.
The densification of ribosomes on transcripts has an additional
consequence: as the number of ribosomes that are stuck on
transcripts increases, more elongation factors are sequestered by
ribosomes. This in turn reduces the probability that an individual
ribosome is bound by a factor—a necessary condition for the
ribosome to attempt a translocation step. This situation results in
a positive feedback loop in which the reduced translocation
attempt rate further amplifies ribosome congestion.
To compare measured and predicted surfaces, which have
different axes, we calculated their respective deviation from
independence as for the bottleneck dependency score (Fig. 3d and
Supplementary Fig. 3). By this measure, the model faithfully
captured the clear deviation from the multiplicative expectation
(Fig. 6f); the agreement with the experimental data is good,
especially considering that the model results are parameter-free
and not a fit to the experimental data.
Taken together, these results show that suppressive drug
interactions between translation inhibitors are caused by the
interplay of two different translation bottlenecks. Close agree-
ment of the experiments with a plausible theoretical model of
ribosome traffic, which captures physiological feedback mediated
by growth laws, strongly suggests that suppression is caused by
ribosome traffic jams. Such traffic jams result from imbalances
between translation initiation and translocation; they dissolve in a
phase transition that occurs when one of these processes is
slowed, leading to an overall acceleration of translation and
growth. Stalled ribosomes facilitate the formation of traffic jams
by sequestering elongation factors. We conclude that a non-
equilibrium phase transition in ribosome traffic is at the heart of
suppressive drug interactions between antibiotics targeting
translation initiation and translocation.
Discussion
We established a framework that combines mathematical mod-
eling, high-throughput growth rate measurements, and genetic
perturbations to elucidate the underlying mechanisms of drug
interactions between antibiotics inhibiting translation. Kinetics of
antibiotic-target binding and transport together with “growth
laws”, i.e., the physiological response to translation inhibition
(Fig. 2), form a biophysically realistic baseline model for
predicting antibiotic interactions from properties of individual
antibiotics alone. This model explained many interactions, but
not all, failing specifically for suppressive interactions. Predictions
improved by taking into account the step-wise progression of
ribosomes through the translation cycle (Figs. 4, 5). This was
achieved by mimicking antibiotic perturbations of this progres-
sion genetically, which directly identified the contribution of
antibiotic-imposed translation bottlenecks to the observed drug
interactions. Finally, to explain the origin of suppressive inter-
actions unaccounted for by the biophysical model, we modeled
the traffic of translating ribosomes explicitly. Our results show
that translocation inhibition can cause ribosomal traffic jams,
which dissolve in a non-equilibrium phase transition when
initiation is inhibited simultaneously with translocation, thereby
restoring growth (Fig. 6). This phase transition explains the
suppressive drug interactions between antibiotics targeting
initiation and translocation.
Taken together, our framework mechanistically explained 20
out of 28 observed drug interactions (Fig. 1 and Supplementary
Figs. 2, 5), as classified based on stringent criteria (Supplementary
Information). While 16 out of 28 interactions were already
explained by the biophysical model, these include many weak and
additive interactions; in contrast, only the translation bottleneck
approach correctly predicted some of the strongest interactions
and, in particular, suppression. Furthermore, we only classified
predictions as correct if the majority of growth rates across the
dose–response surface quantitatively matched the prediction. As a
result, cases where the predicted and observed drug interaction
type agree, are often still classified as false because the agreement
is not quantitative. If the same stringent criteria are applied to
replicate measurements of drug interactions (Supplementary
Fig. 1), only 75% of measurement replicates are classified as
faithful predictions. Thus, our conservative estimate of the frac-
tion of explained interactions (71%) is close to the maximum
achievable at our measurement precision. Notably, even cases
rejected as quantitatively different can provide valuable insights.
For example, the remapping-based prediction of the CHL-FUS
interaction (Fig. 5f) is rejected because it quantitatively exagge-
rates the suppression between these drugs. Nevertheless, remap-
ping correctly predicts the occurrence of suppression as well as its
direction. Qualitative observations like these still advance our
understanding of drug interactions by highlighting drug inter-
action mechanisms that are distorted by additional effects of
unknown origin.
While we focused on translation inhibitors, key elements of our
framework can be generalized to drugs with other modes of
action. Specifically, when considering a drug that targets a specific
process mediated by an essential enzyme, our approach of
equating the deprivation of the enzyme with the action of an
antibiotic is readily applicable. Our observations also highlight
the advantages of factor deprivation compared to simple over-
expression: the former produced a quantitative prediction for
drug interactions, while no meaningful prediction could be made
from overexpression data (Supplementary Fig. 8). The general
approach of depleting key accessory proteins is particularly useful
for antibiotics targeting multi-component complexes or in cases
where the effects of overexpressing the drug target are difficult to
interpret35.
Mimicking the effects of two drugs with controllable genetic
perturbations generalizes the concept of genetic epistasis to
continuous perturbations. Epistasis studies compare the effects of
double gene knockouts to those of single knockouts and identify
epistatic interactions—an approach that can reveal functional
modules in the cell6,37,46. Our results show that continuous
genetic perturbations provide valuable additional information on
genetic interactions (Fig. 6). Firstly, the direction of epistatic
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interactions cannot be extracted from measurements of single and
double mutants. Secondly, the quantitative information obtained
from such “continuous epistasis” measurements provides more
stringent constraints for mathematical models of biological sys-
tems. In particular, continuous epistasis data can be powerful for
the development of whole-cell models that describe the interplay
of different functional modules in the cell. Thirdly, this approach
allows including essential genes in epistatic interaction networks
even for haploid organisms, which otherwise requires the use of
less well-defined hypomorphs. Hence, continuous epistasis mea-
surements augment all-or-nothing genetic perturbations.
Continuous epistasis measurements further enable a deeper
understanding of previously mysterious antibiotic resistance
mutations. Specifically, translation bottlenecks that alleviate the
effect of an antibiotic expose a latent potential for resistance
development. Indeed, mutations with effects equivalent to factor-
imposed bottlenecks occur under antibiotic selection pressure.
For example, resistance to ERM in E. coli can be conferred by
mutations in proteins of the large ribosomal subunit, that hinder
its maturation and lower its stability47. Consistent with this
observation, our results indicate that the action of ERM is alle-
viated by lowering the stability of the 50S subunit (Fig. 3d).
Mutations in recycling factor were observed in Pseudomonas
aeruginosa evolved for resistance to the TET derivative tigecy-
cline48. The observed alleviation of TET action by a recycling
bottleneck (Fig. 3d) offers a mechanistic explanation for the
beneficial effects of these mutations. Mutations in other genes
predicted based on the effect of translation bottlenecks may be
difficult to observe, especially in clinical isolates, due to the
associated fitness cost and selection pressure for reverting the
mutations in the absence of antibiotic selection. Beyond muta-
tions conferring resistance to individual drugs, consistent or
conflicting dependencies of different antibiotics on translation
bottlenecks may further indicate the potential for evolving cross-
resistance and collateral sensitivity, respectively49.
Our work also demonstrates the potential of improved null
models for drug interactions that are based on generic biophysical
and physiological considerations. The number of parameters is
minimal and the biophysical model we presented makes
parameter-free predictions. This model is readily extended to
capture phenomena such as an inactive fraction of ribosomes
(Supplementary Information) or physical interactions between
antibiotics on the ribosome23. Including more detailed mechan-
isms, e.g., the interplay between different ribosome states that are
targeted by different antibiotics, would require additional para-
meters with unknown values. In essence, such a detailed model
and its parameters would have to be fine-tuned for every anti-
biotic combination. Meaningful predictions would require inde-
pendent quantitative measurements of multiple kinetic
parameters such as the rates of antibiotic binding to the ribosome
in different states; for all practical purposes, such a more detailed
model would not be predictive. In contrast, the minimal bio-
physical model we presented provides an improved null expec-
tation for drug interactions. Deviations from this expectation
expose drug interactions for which additional details of the
antibiotic-ribosome interaction are important. We showed
examples of the latter experimentally by halting the ribosome in
specific stages of the translation cycle (Fig. 5). Developing a fully
parameterized mathematical model of the translation cycle and
how it is affected by different antibiotics is a formidable challenge
for decades to come.
Crucial to both the minimal biophysical (Fig. 2) and the
TASEP-translation model (Fig. 6) is the validity of the growth
laws. By experimental validation of such models, we showed that
capitalizing on growth laws in theoretical models can offer
valuable insights into the interplay of cell physiology and
antibiotic action. Unexplained deviations are good starting points
for the identification of situations in which growth laws are
violated. This underscores the importance of elucidating such
growth laws in other organisms.
In conclusion, we presented a systematic approach for dis-
covering the mechanistic origins of drug interactions between
antibiotics targeting translation. As the translation machinery is
highly conserved, the interaction mechanisms for drugs targeting
specific steps of translation we uncovered may generalize to
diverse other organisms. Our approach of mimicking drug effects
with continuous genetic perturbations is general and can be
extended to antibiotics with other primary targets, other types of
drugs, and other organisms. Our quantitative analysis relies on
the established correlation between ribosome content and growth
rate in varying growth environments13. In the long run, extending
our combined experimental-theoretical approach to other types
of drugs and other biological systems will enhance our under-
standing of drug modes of action and interaction mechanisms
and provide deeper insights into cell physiology.
Methods
Bacterial strains. Escherichia coli K-12 MG1655 strain was used as a wild-type
(WT) strain. When necessary, the selection on kanamycin was performed at
25 μg mL−1 (for post-recombineering selection, see below) or at 50 μg mL−1
(for P1 transduction and plasmid selection). A concentration of 100 μg mL−1
was used for ampicillin (pCP20, resistance cassette resolution) and spectino-
mycin (pSIM19, recombineering). The selection for overexpression plasmids
was done at 35 μg mL−1 of chloramphenicol.
To measure the bioluminescence time traces, pCS-λ bearing the bacterial
luxCDABE operon driven by the constitutive λ-PR promoter was transformed into
the strains of interest16. Selection for the luminescence plasmid was used during the
preparation of glycerol stocks (kanamycin 50 μg mL−1) but was omitted during the
measurements to avoid unknown interactions between the antibiotics used. The
plasmid was stably maintained as we observed no significant fitness defect due to
pCS-λ and no apparent spontaneous loss of the plasmid as verified by plating on
selective and non-selective plates (Supplementary Fig. 7). To this end, we tracked
the growth of bacterial cultures in flasks, shaking in a water bath in four conditions.
We either actively selected for plasmid maintenance and/or applied antibiotic stress
by adding 2 μg mL−1 of CHL, which led to ≈50% inhibition. We measured optical
density by standard methods (using Hitachi U-5100 cuvette spectrophotometer);
after each measurement, we replenished 1 mL of removed medium with fresh,
prewarmed medium and corrected the optical density measurements accordingly.
After reaching the late exponential phase, we promptly diluted the culture serially
and plated equal volumes on both selective and non-selective plates.
The translation factor titration platform was established in strain HG105
(MG1655 ΔlacIZYA)50. Briefly, endogenous genes encoding for translation factors
were first sub-cloned into the pKD13 vector under the control of PLlacO−1 promoter
with FRT-flanked kanamycin resistance cassette (kanR) and TrrnB terminator
upstream and downstream of the gene, respectively13,27,36,51. The tandem of kanR
and a gene with all regulatory elements was integrated into the chromosome (galK
locus) using λ-red recombineering (plasmid pSIM1952). The kanamycin resistance
cassettes here and in the following steps were resolved using yeast FLP resolvase
expressed from pCP2053. Loss of the resistance cassette and curing of the pCP20
plasmid were checked by streaking on selection agar plates with antibiotics and by
junction PCR (for resolution). Following the resolution of kanR, the endogenous
factor was inactivated by in-frame deletion: kanR was integrated into the gene locus
and then resolved, which left a 34 residue peptide51. We were unable to introduce
kanR directly into the strain with PLlacO−1 driven frr; therefore, we first performed
the deletion in an auxiliary strain MG1655 bearing the ASKA plasmid with frr54
[JW0167(-GFP)], which complemented the chromosomal deletion when IPTG was
added. The deletion was possible in the auxiliary strain, yielding MG1655 Δfrr::
kanR. We then moved the deletion by generalized P1 transduction55. For tufAB, we
P1-transduced the deletions (ΔtufA::kanR and ΔtufB::kanR) sequentially from the
respective gene deletion strains from the KEIO collection56. All other deletions
were performed directly in the strains of interest using λ-red recombineering using
pKD13 as a template for the cassette amplification51. In the last step, lacI driven by
the PLlacO−1 promoter (yielding growth-rate independent negative
autoregulation13,36) together with the FRT-flanked kanR was integrated into the
intS locus and the resistance cassette was resolved. The allele ΔintS::kanR-PLlacO−1-
lacI-TrrnB was moved into the strains by generalized P1 transduction. All
chromosomal modifications were validated by PCR. The factor titration platform
and the repressor operon were Sanger-sequenced at the integration junctions using
PCR primers or a primer binding into the kanR promoter region (which is
upstream of the PLlacO−1 promoter prior the resolution). The final genotype for the
strains bearing the factor titration platforms is HG105 ΔgalK::frt-PLlacO−1-x Δx::frt
ΔintS::frt-PLlacO−1-lacI, where x denotes the chosen factor. These strains contained
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no plasmids and no antibiotic resistance cassettes but had a single copy of a
translation factor under inducible control.
To generate the strain with independently regulated initiation and translocation
factors, we started with a strain carrying a single infB copy driven by PLlacO−1.
Then, the negatively autoregulated tetR repressor was integrated into the
chromosome, followed by FLP resolvase-mediated resolution of the selection
marker. This enabled the integration of PLtetO-1-driven fusA into the intS locus; the
resolution was followed by the disruption of the endogenous copy of fusA.
Furthermore, we introduced a negatively autoregulated lacI into the xylB locus.
This yielded a marker-less strain with the two essential genes infB and fusA under
inducible, negatively autoregulated, and independent control. The final genotype is:
HG105 ΔgalK::frt-PLlacO−1-infB ΔinfB::frt ΔycaCD::frt-PLtetO−1-tetR ΔintS::frt-
PLtetO−1-fusA ΔfusA::frt ΔxylB::frt-PLlacO−1-lacI. Oligonucleotide sequences,
targeted template, restrictions sites (when used), and a brief description of use are
listed in Supplementary Data 1. All DNA modifying enzymes and Q5 polymerase
used in PCR were from New England Biolabs.
We constructed overexpression strains by transforming HG105 with pCS-λ and
plasmids from the ASKA library54 and its derivatives. We used ASKA plasmids in
which GFP has been excised from the reading frame; we had to repeat the excision
of GFP from the infB-bearing plasmid by NotI digestion and subsequent ligation as
per ref. 54. All plasmids were Sanger-sequenced. For controls we used (i) plasmid
pAA31 (gift from A. Angermayr), in which the open reading frame is cleanly
deleted, as transcription-only control, and (ii) the ASKA plasmid bearing lacZ as a
neutral protein overexpression control. We note that the overexpression of proteins
leads to growth inhibition13,57; hence, we actively selected for plasmid maintenance
by adding 35 μg mL−1 of chloramphenicol into the growth medium.
Growth rate assay and two-dimensional concentration matrices. Rich lysogeny
broth (LB) medium, which at 37 °C supports a growth rate of 2.0 ± 0.1 h−1, was
used. LB medium was prepared from Sigma Aldrich LB broth powder (L3022), pH-
adjusted to 7.0 by adding NaOH or HCl, and autoclaved. Antibiotic stock solutions
were prepared from powder stocks (for catalog numbers, see Supplementary
Table 1), dissolved either in ethanol (CHL, ERM, and TET), DMSO (LAM and
TMP) or water (KAN, CRY, LCY, KSG, FUS, and STR), 0.22 μm filter-sterilized
and kept at −20 °C in the dark until used. Antibiotics were purchased from Sigma
Aldrich or AvaChem. Some of the antibiotics (e.g., ERM, FUS, and LCY) are not
used in the clinic against certain Gram-negative bacteria due to generally poor
efficacy; however, at higher concentrations (yet still well below the solubility limit)
inhibition of growth is observed.
A previously established growth-rate assay based on photon counting was used
to precisely quantify the absolute growth rates for 5–9 generations16. Cultures were
grown in 150 μL of media in opaque white 96-well microtiter plates (Nunc 236105),
which were tightly sealed by transparent adhesive foils (Perkin-Elmer 6050185
TopSeal-A PLUS) to prevent contamination and evaporation. We prepared
glycerol stocks of WT and factor-titration platform strains from saturated
overnight cultures. We inoculated the cultures with ~102 cells per well (1:106
dilution) from either thawed glycerol stocks (for the drug interaction network) or
from liquid cultures in which we first incubated the bacteria containing the factor
titration-platform for 1 h in the absence of IPTG (inoculated by 1:2000 dilution of
the glycerol stock) to partially dilute out the remaining factor molecules before
additional 1:1000 dilution into measurement plates. Between 10 and 20 plates were
cycled through a plate reader using a stacking system (Tecan M1000, controlled by
Tecan i-control software, v1.10.4). We built a custom incubator box around the
stacker towers to facilitate ventilation and fix the temperature to 37 °C
(Supplementary Fig. 7). This incubator was designed and troubleshot by B.K. and
Andreas Angermayr (IST Austria and University of Cologne) and built by IST
Miba Machine Shop. Each plate was read every 20–40 min and was shaken (orbital
10 s, 582 rpm) immediately before reading (settle time 10 ms, integration time 1 s).
Plates were manually pipetted and concentration gradients of antibiotics and
inducers (IPTG, aTc) were prepared by serial dilution (0.70-fold).
Growth rates were determined as a best-fit slope of a linear function fitted to the
log -transformed photon counts per second. The fitting procedure and examples of
growth curves are shown in Supplementary Fig. 1. In rare cases of occurrence of
mutants (as evidenced by sudden growth) we manually removed the measurement
(only in the case of tufA titration). We verified that the luminescence-based
technique leads to the same results as a classical optical density-based one
(Supplementary Fig. 7).
Normalization of dose–response surfaces. All growth rates were normalized
relative to the average growth rate in the drug-free medium [for factor-titration strains
at the highest inducer concentration (5 mM)]. Small differences between individual
dose–response curves were inevitable due to known challenges of preparing identical
concentrations gradients on different days. To correct for such day-to-day variability,
we rescaled the concentration units to the IC50 for each drug. The IC50 was obtained
from fitting the Hill function yðxÞ ¼ 1= 1þ x=IC50ð Þn½  to the individual
dose–response curves. The dose–response curve of each drug was measured seven
times and averaged. The IC50 and corresponding errors reported in Table 1 are
extracted from such average dose–response curves (Supplementary Fig. 1g). Induction
curves were normalized slightly differently, using a shifted and increasing Hill
function in the form gðbÞ ¼ ½ðbþ b0Þ=IC50n= 1þ ðbþ b0Þ=IC50½ nf g, where b0
is a concentration offset. The latter parameter was required as the complete cessation
of growth was not achievable in some cases even in the absence of inducer as
the promoter PLlacO−1 is leaky. Inducer concentrations were thus rescaled via
b→ (b+ b0)/IC50.
Smoothing of dose–response surfaces. To reduce noise when plotting response
surfaces, we smoothed the data using a custom Mathematica script that imple-
ments locally weighted regression (LOESS)58. This approach only smoothed the
contours and did not alter the character of dose–response surfaces. Smoothing was
only used for plotting and not for the analysis in which only interpolation between
adjacent points was used (Mathematica function Interpolation).
Statistics and reproducibility. We measured the dose–response surfaces for all 28
drug interactions in duplicate. As the dose–response surface was measured over a
12 × 16 grid, the duplicates swap the drug axes (12 × 16→ 16 × 12 across two 96-
well plates) on different days to check for effects coming from spreading the
measurements over different plates. The experimental and analysis procedure led
to reproducible measurements of growth rates between days (Supplementary Fig. 1,
ρ ≈ 0.86). For the double factor titration experiment, the inducer gradients were set
up across 6 plates to form a 24 × 24 grid. Each response surface is thus based on
multiple measurements and the impact of individual points is assessed by boot-
strapping. In total, we measured over 20,000 growth curves. We automatized the
collection and analysis of the data to allow for unbiased interpretation of the data.
We characterized the type of drug interaction by calculation of the Loewe
interaction score [Supplementary Equation (1)]. The effects of bottlenecks on the
efficacy of antibiotics were quantified by calculating the bottleneck dependency
score [Supplementary Equation (2)]. To classify the interactions between
antibiotics and antibiotic-bottleneck pairs, we estimated the null distributions by
bootstrapping (Supplementary Information).
We assessed the accuracy of our predictions by “isobole sliding,” which
measures the average deviation of measured isoboles from predicted ones
(Supplementary Information). We performed bootstrapping to statistically
determine the significances of predictions.
A biophysical model for a pair of antibiotics. We constructed a minimal
mathematical model describing the combined antibiotic action based on growth
laws13 and kinetics of antibiotic transport and binding14. The corresponding sys-
tem of coupled ordinary differential equations (ODEs) and additional analysis are
specified in the Supplementary Information. Differential equations describe the
time-evolution of unbound, individually-bound and double-bound ribosomes, as
well as the intracellular concentrations of antibiotics. Growth laws convert the
concentration of unbound ribosomes into the growth rate, which determines the
total abundance of ribosomes13,14. Steady-state solutions were found numerically.
A more detailed analysis of model extensions is reported in ref. 23.
TASEP model of translation. We developed a mean-field mathematical model of
factor-mediated translation which recovers the suppression between inhibitions of
initiation and translocation. We took into account that ribosomes can perform a
specific step only when bound by a corresponding translation factor. The mathe-
matical framework is detailed in Supplementary Methods followed by a Supple-
mentary Discussion of the effect of mRNA growth-rate dependence, rescue
mechanisms, and inefficiency of a direct response to translocation inhibition.
Materials availability. Strains described in this study can be obtained from the
corresponding author upon reasonable request.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data to produce all figures are available in Source Data, oligonucleotides are listed in
Supplementary Data 1. Source data are provided with this paper. Minimally processed
raw data is publicly available at https://doi.org/10.15479/AT:ISTA:8097 together with
analysis scripts. Source data are provided with this paper.
Code availability
The scripts for the mathematical models and for the data analysis were implemented in
Mathematica 11.3 (Wolfram Research). The scripts have been deposited to IST DataRep
and are publicly available at https://doi.org/10.15479/AT:ISTA:8097. Source data are
provided with this paper.
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